Enora Laas

2.5k total citations · 2 hit papers
97 papers, 1.5k citations indexed

About

Enora Laas is a scholar working on Oncology, Cancer Research and Obstetrics and Gynecology. According to data from OpenAlex, Enora Laas has authored 97 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 33 papers in Cancer Research and 24 papers in Obstetrics and Gynecology. Recurrent topics in Enora Laas's work include Breast Cancer Treatment Studies (28 papers), Endometrial and Cervical Cancer Treatments (19 papers) and Ovarian cancer diagnosis and treatment (15 papers). Enora Laas is often cited by papers focused on Breast Cancer Treatment Studies (28 papers), Endometrial and Cervical Cancer Treatments (19 papers) and Ovarian cancer diagnosis and treatment (15 papers). Enora Laas collaborates with scholars based in France, United States and Switzerland. Enora Laas's co-authors include Fabien Reyal, Anne‐Sophie Hamy, Émile Daraï, Roman Rouzier, Anne Vincent‐Salomon, Jean‐Yves Pierga, Marick Laé, Marcos Ballester, Geoffroy Canlorbe and Jean-Guillaume Féron and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and PEDIATRICS.

In The Last Decade

Enora Laas

86 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipid-Associated Macrophages Are Induced by Cancer-Associated Fibroblasts and Mediate Immune Suppression in Breast Cancer

2022 173 citations Eleonora Timperi, Paul Gueguen et al. Cancer Research profile →
Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective

2024 67 citations Paul Gougis, Floriane Jochum et al. EClinicalMedicine profile →

Peers

Countries citing papers authored by Enora Laas

Since Specialization

Citations

This map shows the geographic impact of Enora Laas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enora Laas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enora Laas more than expected).

Fields of papers citing papers by Enora Laas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Enora Laas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enora Laas. The network helps show where Enora Laas may publish in the future.

Co-authorship network of co-authors of Enora Laas

This figure shows the co-authorship network connecting the top 25 collaborators of Enora Laas. A scholar is included among the top collaborators of Enora Laas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enora Laas. Enora Laas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Impact of Fat Graft Reconstructive Surgery on Prognosis in Young Women with Breast Cancer: A Study from the French Insurance Databases 2025 ·Plastic & Reconstructive Surgery ·Enora Laas, Thomas Gaillard, Benoît Couturaud, Lauren Darrigues, Élise Dumas, Anne‐Sophie Hamy, Jean-Guillaume Féron, Fabien Reyal, François Husson, Anne‐Sophie Jannot	0
2	Predicting axillary residual disease after neoadjuvant therapy in breast cancer using baseline MRI and ultrasound 2025 ·European Radiology ·Caroline Malhaire, (unknown), Vincent Cockenpot, (unknown), Toulsie Ramtohul, Fabien Reyal, Jean‐Yves Pierga, Emanuela Romano, Anne Vincent‐Salomon, Youlia Kirova, Enora Laas, Hervé J. Brisse, Frédérique Frouin	0
3	BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase 2025 ·Clinical Pharmacology & Therapeutics ·Aurélie Cabannes‐Hamy, (unknown), Floriane Jochum, Kévin Bihan, Élise Dumas, Florence Coussy, Enora Laas, Philippe Rousselot, Sylvain Choquet, Madalina Uzunov, Laurent Salomon, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis	0
4	Minimally invasive simple hysterectomy in low-risk cervical cancer: a single-arm trial with stopping rules (ENGOT-cx23/MITO/LASH trial) 2025 ·International Journal of Gynecological Cancer ·Nicolò Bizzarri, Denis Querleu, (unknown), Marie Plante, Diana Giannarelli, Henrik Falconer, Nadeem R. Abu‐Rustum, David Cibula, Alejandra Martínez, Enora Laas, Christina Fotopoulou, Luis Chiva, Matteo Pavone, Luigi Pedone Anchora, Francesco Fanfani, Anna Fagotti, Giovanni Scambia	2
5	Magnetic surgical marker navigation for excision of non-palpable ultrasound visible breast lesions: first 200 cases in a French cancer center 2025 ·Scientific Reports ·(unknown), (unknown), (unknown), Thomas Gaillard, (unknown), Lauren Darrigues, (unknown), (unknown), Émilie Raimond, (unknown), Olivier Graesslin, (unknown), Enora Laas, Fabien Reyal, (unknown), Judicaël Hotton	1
6	Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib 2024 ·British Journal of Cancer ·Thomas Gaillard, (unknown), Jean-Guillaume Féron, (unknown), (unknown), (unknown), Lauren Darrigues, (unknown), Jean‐Yves Pierga, Anne‐Sophie Hamy, Fabien Reyal, Enora Laas	7
7	Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective breakdown → 2024 ·EClinicalMedicine ·Paul Gougis, Floriane Jochum, Baptiste Abbar, Élise Dumas, Kévin Bihan, Bénédicte Lebrun‐Vignes, Javid J. Moslehi, Jean‐Philippe Spano, Enora Laas, Judicaël Hotton, Fabien Reyal, Anne‐Sophie Hamy, Joe‐Elie Salem	67
8	Sex-related differences in oncological surgery and postoperative outcomes: comprehensive, nationwide study in France 2024 ·British journal of surgery ·Floriane Jochum, Anne‐Sophie Hamy, Paul Gougis, Élise Dumas, (unknown), (unknown), Enora Laas, Jean-Guillaume Féron, Virginie Fourchotte, Thomas Gaillard, (unknown), (unknown), (unknown), Lauren Darrigues, Judicaël Hotton, Lise Lecointre, Fabien Reyal, Fabrice Lécuru, Chérif Akladios	2
9	Use of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy 2024 ·Radiology ·Toulsie Ramtohul, (unknown), Claire Bonneau, (unknown), Emmanuelle Menet, (unknown), Enora Laas, Emanuela Romano, (unknown), (unknown), Anne Vincent‐Salomon, François‐Clément Bidard, A. Langer, Caroline Malhaire, Luc Cabel, Hervé J. Brisse, A. Tardivon	14
10	Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation 2024 ·American Journal of Obstetrics and Gynecology ·Floriane Jochum, Élise Dumas, Paul Gougis, Anne‐Sophie Hamy, Denis Querleu, (unknown), Thomas Gaillard, Fabien Reyal, Fabrice Lécuru, Enora Laas, Chérif Akladios	4
11	Lipid-Associated Macrophages Are Induced by Cancer-Associated Fibroblasts and Mediate Immune Suppression in Breast Cancer breakdown → 2022 ·Cancer Research ·Eleonora Timperi, Paul Gueguen, Martina Molgora, Ilaria Magagna, Yann Kieffer, (unknown), Philémon Sirven, Laura G. Baudrin, Sylvain Baulande, Nicolás André, Gabriel Champenois, Didier Meseure, Anne Vincent‐Salomon, A. Tardivon, Enora Laas, Vassili Soumelis, Marco Colonna, Fatima Mechta‐Grigoriou, Sebastián Amigorena, Emanuela Romano	173
12	The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS) 2022 ·Cancers ·Élise Dumas, (unknown), Florence Coussy, (unknown), (unknown), Enora Laas, (unknown), (unknown), (unknown), Floriane Jochum, Paul Gougis, (unknown), (unknown), Christine Le Bihan-Benjamin, Philippe‐Jean Bousquet, Judicaël Hotton, Chloé‐Agathe Azencott, Fabien Reyal, Anne‐Sophie Hamy	14
13	The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer 2021 ·Cancers ·Julie Labrosse, (unknown), (unknown), Enora Laas, Jean-Guillaume Féron, Florence Coussy, Marick Laé, Fabien Reyal, Anne‐Sophie Hamy	5
14	The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes 2021 ·Cancers ·(unknown), Enora Laas, (unknown), Élise Dumas, (unknown), (unknown), Jean‐Yves Pierga, Florence Coussy, Youlia Kirova, (unknown), Guillaume Bataillon, Marick Laé, (unknown), Fabien Reyal, Anne‐Sophie Hamy	6
15	HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens 2021 ·Cancers ·Enora Laas, (unknown), Jean-Guillaume Féron, (unknown), Lauren Darrigues, Florence Coussy, (unknown), (unknown), Jean‐Yves Pierga, Fabien Reyal, Anne‐Sophie Hamy	6
16	Time to Pregnancy, Obstetrical and Neonatal Outcomes after Breast Cancer: A Study from the Maternity Network for Young Breast Cancer Patients 2021 ·Cancers ·Julie Labrosse, (unknown), (unknown), (unknown), (unknown), Enora Laas, Florence Coussy, (unknown), Élise Dumas, (unknown), (unknown), Jean-Guillaume Féron, Matthieu Faron, Jean‐Yves Pierga, Fabien Reyal, Anne‐Sophie Hamy	5
17	Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore 2021 ·British Journal of Cancer ·Enora Laas, Julie Labrosse, Anne‐Sophie Hamy, (unknown), Diane De Croze, Jean-Guillaume Féron, Florence Coussy, (unknown), Julien Guérin, Marick Laé, Jean‐Yves Pierga, Fabien Reyal	22
18	Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy 2020 ·PLoS ONE ·Anne‐Sophie Hamy, Lauren Darrigues, Enora Laas, Diane De Croze, (unknown), (unknown), (unknown), (unknown), (unknown), Florence Lerebours, Jean‐Yves Pierga, Marie Osdoit, Matthieu Faron, Jean-Guillaume Féron, Marick Laé, Fabien Reyal	53
19	Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy 2019 ·Clinical Cancer Research ·Anne‐Sophie Hamy, Hélène Bonsang‐Kitzis, Diane De Croze, Enora Laas, Lauren Darrigues, (unknown), Emmanuelle Menet, Anne Vincent‐Salomon, Florence Lerebours, Jean‐Yves Pierga, Étienne Brain, Jean-Guillaume Féron, (unknown), (unknown), Marick Laé, Fabien Reyal	50
20	Analyse coût-efficacité d’un test prédictif de la chimiothérapie dans le cancer du sein (Oncotype DX®) en France 2012 ·Bulletin du Cancer ·A.L. Vataire, Enora Laas, Samuel Aballéa, Joseph Gligorov, Roman Rouzier, E. Chéreau	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact